Biodexa Pharmaceuticals held general meeting, shareholders passed four resolutions
BDRX•Shareholders approve four resolutions
Biodexa Pharmaceuticals held a general meeting earlier today, passing all resolutions put to shareholders.
- Share capital reorganization was adopted, cutting ordinary shares outstanding by a factor of 10,000 while keeping par value at GBP 0.000001.
- The ordinary share-to-ADS ratio change was also adopted, shifting to 50:1 from 500,000:1.
- Execution is scheduled for July 30, 2026; proportional ownership is expected to remain unchanged, subject to fractional entitlements.
- Directors received authority to allot ordinary shares on a non-pre-emptive basis.
